Project Grant R01AI192330
Award Date
6/10/25
Completion Date
5/31/30
Dollars Obligated
$1.3M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This $800,389 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key products or services to be delivered include: Comprehensive testing of the effects of IL-15/IL-15RA-FC therapy combined with TGF-beta blockade (Galunisertib) on different T and NK cell...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,356,188 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University to characterize the HIV-1 proviral pool in neonates and infants receiving very early and enhanced early antiretroviral therapy (ART) and broadly neutralizing antibodies (bNAbs) towards achieving ART-free remission. The project aims to quantify and analyze the intact proviral reservoir,...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $2,688,880 Project Grant to Emory University to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key products and services to be delivered under this grant include: Comprehensive testing of the effects of IL-15/IL-15RA therapy combined with TGF-beta blockade on different T and NK cell...
This federal Project Grant award of $1,766,954.46 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the immune microenvironments that impact HIV persistence and expression during antiretroviral therapy (ART). The key objectives are to: 1) Determine the location, phenotype, and microenvironment of HIV viral RNA (vRNA)-expressing cells in secondary lymphoid tissues of...
This Project Grant award for $1,314,572.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at developing a cure strategy for HIV-1 using CD4-mimetic compounds (CD4MCs) and CD4-induced antibodies (CD4I Abs). The research, conducted by Yale University, leverages the recent discovery of a new class of indoline CD4MCs that display improved antiviral potency and breadth...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,420,190 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of California, Davis. The goal of this 5-year project is to understand the reservoir effects and curative potential of a CD3/CCR5 bispecific antibody when administered to infants in the early stages of SIV (simian immunodeficiency virus) infection. The researchers will screen infants to identify those with limited or...
The federal Project Grant award R01AI187016 for $737,761.00, awarded on August 1, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (TFH) cells, which are essential for vigorous B cell activity within germinal centers, to facilitate the...
This $499,550 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research into understanding and controlling the latent HIV reservoir in memory CD4+ T cells. The key objectives are to investigate how the BACH2 transcription factor regulates the terminal differentiation of CCR5+ CD4+ T cells, which are the primary targets for HIV infection and reservoir establishment. The...
This $812,810 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Emory University to generate highly differentiated natural killer (NK) cells and evaluate their synergistic effects with broadly neutralizing antibodies in reducing the SIV reservoir and establishing viral control in the absence of antiretroviral therapy (ART). The key objectives are to: 1) define...
This $3,454,926 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research aimed at developing an HIV-1 vaccine strategy focused on the "apex" epitope of the HIV envelope glycoprotein. The research seeks to identify and characterize HIV broadly neutralizing antibody (bNAb) precursors that target the apex epitope, and to design envelope protein antigens that can...